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ABSTRACT 
Macrophage migration inhibitory factor (MIF) has an important role in controlling infection. The aim of this 
study was to evaluate the possible association between MIF -173 G/C functional polymorphism and pulmonary 
tuberculosis (PTB) in an Iranian population from Zahedan Southeast Iran. This case-control study was done on 
161 PTB and 142 healthy subjects. Genomic DNA was extracted from all participants by salting out method. 
The MIF -173 G/C variant was genotyped using polymerase chain reaction-restriction fragment length polymor-
phism (PCR-RFLP). The finding showed that the MIF -173 G/C polymorphism increased the risk of PTB in co-
dominant (OR=1.76, 95 % CI=1.05-2.95, p=0.038, GC vs GG) and dominant (OR=1.78, 95 % CI=1.09-2.91, 
p=0.027, GC+CC vs GG) tested inheritance models. Furthermore, the minor allele frequency (MAF) increased 
the risk of PTB in comparison with G allele (OR=1.63, 95 % CI=1.07-2.48, p=0.028). In conclusion, the present 
study provides evidence that -173 G/C polymorphism may increase the risk of PTB.  
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INTRODUCTION 
Tuberculosis (TB) is caused by the bacil-
lus Mycobacterium tuberculosis and remains 
a major global health problem especially in 
Asia and Africa (Orcau et al., 2011). Accord-
ing to the report of World Health Organiza-
tion, approximately 8.6 million new cases of 
TB were reported in 2012 (Zumla et al., 
2013). Though one-third of population is in-
fected with TB, merely 10 % of infected cas-
es will develop clinical disease during their 
lifetime. Multiple factors contribute to the 
risk of infection and development of TB in-
cluding environmental factors, host–
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pathogen interactions and genetic factors 
(Bellamy, 2003). Increasing evidence indi-
cates that the risk of developing tuberculosis 
in human is strongly influenced by genetic 
factors (Azad et al., 2012). 
Human macrophage migration inhibitory 
factor (MIF) gene is located on chromosome 
22q11.2. A functional variant in within the 
5` promoter region of MIF, located at posi-
tion -173 replacing G to C, appears to affect 
promoter activity in a cell-type dependent 
manner (Donn et al., 2002; Renner et al., 
2005). MIF encodes a multifunctional cyto-
kine, MIF, which is produced by several 
types of cells, including epithelial cells and 
cells that participate in the innate and adap-
tive immune responses (Bacher et al., 1997; 
Calandra et al., 1994). MIF protein is a plei-
otropic cytokine produced by activated T 
cells, macrophages, and the pituitary gland 
(Bernhagen et al., 1993; Bloom and Bennett, 
1966; Calandra et al., 1994).  
MIF is considered an immuno-regulatory 
cytokine, and the role of MIF during micro-
bial infection has been recognized to its abil-
ity to initiate an innate immune response by 
inducing tumor necrosis factor-α (TNF-α) 
production and other pro-inflammatory cyto-
kines (Marinho et al., 2007; Roggero et al., 
2002, 2004).  
It has been proposed that gene variants 
play an important role in the occurrence and 
development of TB (Bahari et al., 2012; 
Naderi et al., 2013, 2014a). Several studies 
have shown that MIF -173 G/C variant in-
creased the risk of TB (Gomez et al., 2007; 
Li et al., 2012a; Sadki et al., 2010). To the 
best of our knowledge, there is not any re-
port regarding the impact of this variant on 
TB in Iranian population. Therefore, the pre-
sent study was designed to find out the pos-
sible association between MIF -173 G/C var-
iant and PTB in a sample of Iranian popula-
tion. 
 
MATERIALS AND METHODS 
This case-control study was done on 161 
PTB patients and 142 population-based 
healthy subjects. The subjects who under-
went PTB treatment and newly diagnosed 
PTB cases were enrolled in the study within 
the case group. The diagnosis of PTB was 
based on clinical, radiological, sputum Acid 
Fast Bacillus (AFB) smear positivity, cul-
ture, and response to antituberculosis therapy 
as described previously (Hashemi et al., 
2013; Naderi et al., 2014b). Control subjects 
were selected from the Zahedan population 
showing no recent signs, symptoms, or histo-
ry of pulmonary infections. The local Ethics 
Committee of the Zahedan University of 
Medical Sciences approved the project, and 
written informed consent was taken from all 
individuals. Genomic DNA was extracted 
from whole blood using salting out method 
as described previously (Hashemi et al., 
2010).  
Genotyping of rs755622 polymorphism 
of MIF was done by PCR-RFLP methods. 
The forward and reverse primers were 5`- 
CTCAAACACACAAGCTCACGCATGCG-
3` and 5`-ACCACTGTGGTCCCGCCTTTTG 
TGAC-3`, respectively. In each 0.20 ml reac-
tion, 1 µl of genomic DNA (~100 ng/ml), 1 
µl of each primers and 10 µl of 2X Prime 
Taq Premix (Genet Bio, Korea) and 7 µl 
ddH2O were added. The PCR conditions 
were set as follows: 95 °C for 5 min, 30 cy-
cles of 95 °C for 30 s, 65 ° for 30 s, and 
72 °C for 30 s and a final extension step of 
72 °C for 10 min. Ten microliter of PCR 
product digested by AluI restriction enzyme. 
The C allele digested and produces 255bp 
and 184bp while the G allele undigested and 
produce 439bp fragment.  
 
Statistical analysis 
Statistical analysis was done using statis-
tical package SPSS 18 software (SPSS for 
Windows (SPSS, Inc., IL, USA). Data were 
analyzed by independent sample t-test and χ2 
test. The associations between MIF poly-
morphism and PTB were assessed by com-
puting the odds ratio (OR) and 95 % confi-
dence intervals (95 % CI) from logistic re-
gression analyses adjusted for sex and age. A 
p-value < 0.05 was considered statistically 
significant. We estimated the Hardy-Wein-
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berg equilibrium (HWE) separately for cases 
and controls. 
 
RESULTS 
The study group consists of 161 PTB pa-
tients (61 male, 100 female) and 142 healthy 
subjects (62 male, 80 female). The mean age 
of PTB, and healthy individuals were respec-
tively 50.6 ± 20.5, and 47.3 ± 15.4 years. No 
significant difference was found between the 
groups regarding sex and age (p > 0.05).  
The finding showed that the MIF -173 
G/C polymorphism increased the risk of PTB 
in codominant (OR=1.76, 95 % CI=1.05-
2.95, p=0.038, GC vs GG) and dominant 
(OR=1.78, 95 % CI=1.09-2.91, p=0.027, 
GC+CC vs GG) tested inheritance models.  
Furthermore, the minor allele frequency 
(MAF) of MIF -173 G/C increased the risk 
of PTB in comparison with G allele 
(OR=1.63, 95 % CI=1.07-2.48, p=0.028).  
The genotype of MIF -173 G/C variant in 
controls and cases were in HWE (χ2=1.59, 
P=0.207 and χ2=0.289, P=0.590, respective-
ly) (Table 1). 
 
DISCUSSION 
It has been proposed that the MIF is a 
critical mediator of the innate immune re-
sponse to TB (Das et al., 2013). In the pre-
sent study we investigated the impact of MIF 
-173 G/C (rs755622) functional variant on 
PTB risk in a sample of Iranian population. 
Our findings suggest that rs755622 GC as 
well as GC+CC genotypes increased the risk 
of PTB. Also, subjects with MIF rs755622 C 
allele were found to be more susceptible to 
PTB. 
Gomez et al. (2007) reported that MIF -
173 C allele increased the risk of TB in Co-
lombian population. Li et al. (2012b) inves-
tigated the association between human MIF 
promoter polymorphism and tuberculosis in 
a Southwestern Chinese population. They 
found that the MIF -173 G/C polymorphism 
increased the risk of TB (OR=2.12, 95 % 
CI=1.45–3.10 GC+CC vs. GG). Sadki et al. 
(2010) have found a statistically significant 
increase of the MIF -173 CC homozygote 
genotype and MIF -173 C allele frequencies 
in PTB patients compared with healthy con-
trols in Moroccan population. It has been 
shown that MIF -173 G/C polymorphism is 
not associated with incidence of pulmonary 
hamartoma (Kaznowska et al., 2007).  
It has been shown that serum level of 
MIF was significantly higher in patients with 
pulmonary tuberculosis than in controls (Li 
et al., 2012b; Yamada et al., 2002). High 
levels of serum MIF and interleukin 10 (IL-
10) are shown to be associated with a rapidly 
fatal outcome in patients with severe sepsis 
(Chuang et al., 2014). 
 
 
Table 1: Comparison of genotype frequency of MIF -137 G/C (rs755622) polymorphism in PTB and 
controls 
rs755622 PTB n (%) Control n (%) OR (95 % CI) p-value 
Codominant     
GG 99 (61.5) 105 (74.0) 1.00 - 
GC 53 (32.9) 32 (22.5) 1.76 (1.05-2.95) 0.038 
CC 9 (5.6) 5 (3.5) 1.91 (0.62-5.79) 0.282 
Dominant     
GG 99 (61.5) 105 (74.0) 1.00 - 
GC+CC 62 (38.5) 37 (26.0) 1.78 (1.09-2.91) 0.027 
Recessive     
GG+GC 152 (94.4) 137 (96.5) 1.00 - 
CC 9 (5.6) 5 (3.5) 1.62 (0.53-4.96) 0.426 
Alleles     
G 251 (78.0) 242 (85.2) 1.00 - 
C 71 (22.0) 42 (14.8) 1.63 (1.07-2.48) 0.028 
EXCLI Journal 2015;14:117-122 – ISSN 1611-2156 
Received: October 17, 2014, accepted: November 26, 2014, published: January 21, 2015 
 
 
120 
Mycobacterium tuberculosis mainly in-
fects macrophages in vivo, which can result 
in substantial macrophage activation, prolif-
eration, recruitment to the site of infection, 
aggregation, invasion, and secretion of sev-
eral cytokines to produce a strong immune 
response which may also cause tissue dam-
age. MIF plays an essential role in the pro- 
and anti-inflammatory response to infection.  
Earlier studies have shown that polymor-
phisms in promoter influence the basal 
and/or induced transcription activity of MIF, 
and the -173 C allele is associated with 
greater production of MIF protein (Donn et 
al., 2002). Higher reporter luciferase activity 
for both the MIF -173 C allele and the MIF 
CATT7-173C haplotype has been founded in 
a human T-lymphoblast cell line (Baugh et 
al., 2002). 
MIF is considered an integral component 
of the host antimicrobial alarm system and 
stress response that promotes the pro-
inflammatory functions of immune cells 
(Calandra et al., 2003). MIF serum levels are 
significantly increased in parasitic diseases 
such as leishmaniasis and malaria 
(Awandare et al., 2007; Chaiyaroj et al., 
2004), and functional polymorphism of the 
human MIF gene has been associated with 
increased susceptibility or severity to in-
flammatory (de Jong et al., 2001; Renner et 
al., 2005), autoimmune (Radstake et al., 
2005; Sanchez et al., 2006; Stosic-Grujicic et 
al., 2009), and infectious diseases (Awandare 
et al., 2006; Gomez et al., 2007). 
In conclusion, our finding provides evi-
dence that MIF -173 G/C functional poly-
morphism may contribute to the risk of PTB 
in a sample of Iranian population. Validation 
by a larger prospective study from an addi-
tional diverse ethnic population is necessary 
to verify the results. 
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